The Life and Times of a Promotional Claims Compendium
By Rebecca Rivera Torres, MS, RD, CSSD -
Published 30 October 2017
This article discusses developing a "promotional claims compendium" to review pharmaceutical marketing materials. It highlights the advantages of using a compendium for a variety of purposes and the potential value it could bring to not only the review team, but the entire organization.
Categories: Features, US, FDA, Advertising and Promotion, Communication, Drugs
Tags: Promotional Materials, Promotional Claims, Brand Book
FDA Warns Fresenius Kabi Subsidiary Over Promotional Materials
By Michael Mezher -
Published 15 February 2017
The US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has warned Fenwal, a Fresenius Kabi subsidiary, for the second time due to promotional materials for the company's platelet additive solution.
Categories: News, US, CBER, Advertising and Promotion, Blood, Compliance, Drugs
Tags: Fenwal, Fresenius Kabi, InterSol, Amicus, Promotional Materials
FDA Making Changes to its Drug Advertising Review Process
By Alexander Gaffney, RAC -
Published 22 April 2015
A new guidance document finalized by the US Food and Drug Administration (FDA) proposes to make it easier for pharmaceutical marketing professionals to submit their advertisements and promotional materials for review by regulators.
Categories: News, US, CDER, Advertising and Promotion
Tags: Form FDA 2253, OPDP, Promotion, Advertising, Promotional Materials, Guidance, Draft Guidance